2,884 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by B&L Asset Management LLC

B&L Asset Management LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,884 shares of the company's stock, valued at approximately $563,000.

A number of other large investors have also recently made changes to their positions in ZTS. Darwin Wealth Management LLC purchased a new stake in Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis in the 3rd quarter worth $33,000. Quarry LP boosted its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after buying an additional 153 shares during the last quarter. Finally, Fortitude Family Office LLC grew its holdings in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company's stock worth $46,000 after acquiring an additional 222 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS traded down $1.49 during trading hours on Friday, reaching $175.25. 1,543,442 shares of the stock traded hands, compared to its average volume of 2,880,750. The company has a market cap of $79.07 billion, a P/E ratio of 32.94, a price-to-earnings-growth ratio of 2.69 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company's 50-day moving average price is $183.83 and its two-hundred day moving average price is $180.92. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business earned $1.36 earnings per share. The business's revenue was up 11.6% on a year-over-year basis. On average, analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis's dividend payout ratio (DPR) is currently 32.33%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ZTS shares. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Argus raised shares of Zoetis to a "strong-buy" rating in a report on Friday, August 9th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a research note on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.